



Material Safety Data Sheet

12601 Twinbrook Parkway,
Rockville, MD 20852 USA

Phone Calls: 301-816-8129
8 a.m. to 5 p.m. EST Mon. - Fri.

ATTENTION !

USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.

TERAZOSIN HYDROCHLORIDE

Catalog Number: 1643452

Revision Date:

November 7, 2006

SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION

Common Name: Terazosin Hydrochloride

Manufacturer: U. S. Pharmacopeia

Responsible Party: Reference Standards Technical Services

Mailing Address: 12601 Twinbrook Parkway, Rockville, MD 20852 USA

Phone: 301-816-8129

Hours: 8 a.m. to 5 p.m. EST Mon. - Fri.

Product Use: USP Reference Standards and Authentic Substances are used for chemical tests and assays in analytical, clinical, pharmaceutical, and research laboratories.

SECTION 2 - HAZARD INFORMATION

EMERGENCY OVERVIEW : Irritant

Adverse Effects: Adverse effects may include dizziness or lightheadedness; chest pain; shortness of breath; swelling of feet or lower legs; sudden fainting; pounding, fast, or irregular heartbeat; unusual tiredness or weakness; headache; back or joint pain; blurred vision; nasal congestion; nausea or vomiting; and drowsiness. Possible allergic reaction to material if inhaled, ingested or in contact with skin.

Overdose Effects: n/f

Acute: Possible eye, skin, gastrointestinal and/or respiratory tract irritation.

Chronic: Possible hypersensitization.

Medical Conditions Aggravated by Exposure: Hypersensitivity to material.

Cross Sensitivity: n/f

Target Organs: Cardiovascular system

For additional information on toxicity, see Section 11.

SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS

Common Name: Terazosin Hydrochloride

Formula: C₁₉H₂₅N₅O₄ . HCl . 2H₂O

Synonym: n/f

TERAZOSIN HYDROCHLORIDE

Catalog Number: 1643452

Revision Date:

November 7, 2006

Chemical Name: Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazoliny)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride, dihydrate

CAS: 70024-40-7

RTECS Number: TK8046000

Chemical Family: Quinazoline derivative

Therapeutic Category: Antihypertensive (alpha1-adrenergic blocker)

Composition: Pure Material

SECTION 4 - FIRST AID MEASURES

Inhalation: May cause irritation. Remove to fresh air.

Eye: Causes irritation. Avoid contact. Flush with copious quantities of water for at least 15 minutes.

Skin: May cause irritation. Flush with copious quantities of water.

Ingestion: May cause irritation. Flush out mouth with water. This material is rapidly and almost completely absorbed from the gastrointestinal tract. Effects may begin in 15 minutes and last up to 24 hours.

General First Aid Procedures: Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not breathing give artificial respiration. If breathing is difficult give oxygen. Obtain medical attention.

Note to Physicians

Overdose Treatment: Overdose treatment should be symptomatic and supportive and may include the following:

1. Treat circulatory failure by placing the patient in the supine position and elevating the legs. Use additional measures if shock is present.
2. Treat shock with volume expanders followed, if necessary, with a vasopressor.
3. Monitor fluid and electrolyte status. [USP DI 2005]

SECTION 5 - FIREFIGHTING MEASURES

Extinguisher Media: Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.

Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

SECTION 6 - ACCIDENTAL RELEASE MEASURES

Spill Response: Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.

SECTION 7 - HANDLING AND STORAGE

Handling: As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

Storage: Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

SECTION 8 - EXPOSURE CONTROL / PERSONAL PROTECTION

Engineering Controls: Engineering controls such as exhaust ventilation are recommended.

Respiratory Protection: Use a NIOSH-approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.

Gloves: Chemically compatible**Eye Protection:** Safety glasses or goggles**Protective Clothing:** Protect exposed skin.**Exposure Limits:** Industry: 10 micrograms/m³

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Properties as indicated on the MSDS are general and not necessarily specific to the USP Reference Standard Lot provided.**Appearance and Odor:** White to light yellow crystalline powder; odorless.**Odor Threshold:** n/f**pH:** 4.0 as a 1% solution**Melting Range:** 271 - 274° C**Boiling Point:** n/f**Flash Point:** n/f**Autoignition Temperature:** n/f**Evaporation Rate:** n/f**Upper Flammability Limit:** n/f**Lower Flammability Limit:** n/f**Vapor Pressure:** n/f**Vapor Density:** n/f**Specific Gravity:** n/f**Solubility in Water:** Soluble**Fat Solubility:** n/f**Other Solubility:** Soluble in methyl alcohol; freely soluble in isotonic saline solution; slightly soluble in alcohol and in 0.1 N hydrochloric acid; practically insoluble in acetone and in hexanes; very slightly soluble in chloroform.**Partition Coefficient: n-octanol/water:** n/f**Percent Volatile:** n/f**Reactivity in Water:** n/f**Explosive Properties:** n/f**Oxidizing Properties:** n/f**Formula:** C₁₉H₂₅N₅O₄ · HCl · 2H₂O**Molecular Weight:** 459.92

TERAZOSIN HYDROCHLORIDE

Catalog Number: 1643452

Revision Date:

November 7, 2006

SECTION 10 - STABILITY AND REACTIVITY

Conditions to Avoid: Avoid exposure to light.

Incompatibilities: n/f

Decomposition Products: When heated to decomposition material emits toxic fumes. Emits toxic fumes under fire conditions.

Stable? Yes **Hazardous Polymerization?** No

SECTION 11 - TOXICOLOGICAL PROPERTIES

Oral Rat: LD50: 5500 mg/kg

Oral Mouse: LD50: >8 grams/kg

Other Toxicity Data: n/f

Irritancy Data: Animal (species not specified)/eye: mild to moderate

Corrosivity: n/f

Sensitization Data: Negative in guinea pig maximization assay.

Listed as a Carcinogen by: **NTP:** No **IARC:** No **OSHA:** No

Other Carcinogenicity Data: There was an increase in benign medullary tumors in male rats at a dose of 250 mg/kg/day for two years. Male rats at lower doses, female rats, and mice did not show evidence of carcinogenicity.

Mutagenicity Data: Both in vivo and in vitro tests found no evidence of mutagenicity.

Reproductive and Developmental Effects: Studies in rats and rabbits given very high doses of terazosin showed an increase in fetal resorptions in rats and an increase in fetal resorptions, decreased fetal weight, and an increased number of supernumerary ribs in rabbits. Birth defects were not found.

SECTION 12 - ECOLOGICAL INFORMATION

Ecological Information: n/f

SECTION 13 - DISPOSAL CONSIDERATIONS

Disposal: Dispose of waste in accordance with all applicable Federal, State and local laws.

SECTION 14 - TRANSPORT INFORMATION

Shipping Name: n/f

Class: n/f

UN Number: n/f

Packing Group: n/f

Additional Transport Information: n/f

SECTION 15 - REGULATORY INFORMATION

U.S. Regulatory Information: n/f

International Regulatory Information: Hazard code: Xi
Risk phrases: R36
Safety phrases: S25, S26

SECTION 16 - OTHER INFORMATION

TERAZOSIN HYDROCHLORIDE**Catalog Number:** 1643452**Revision Date:**

November 7, 2006

Revision: 07-Nov-06**Previous Revision Date:** 18-May-05